AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
← catalyst calendarSponsored by Artiva Biotherapeutics, Inc. (industry) · ARTV — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
45actual
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-29 | actual | When the study began enrolling |
| Primary completion | 2025-10-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-06 | actual | The whole study's end, after follow-up |
| First posted | 2020-12-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Hodgkin Lymphoma
Interventions
- Drug: AB-101
- Drug: Rituximab
- Drug: Interleukin-2
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Drug: Bendamustine
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Safety and tolerability of AB-101 as monotherapy, and in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab.
measured From the ICF signature through 13 weeks after last study drug dose.
Phase 1, combination therapy: AB-101 clinical activity, determined by ORR
measured From baseline disease assessment through end of study participation.
Phase 1, combination therapy: Identify the recommended Phase 2 dose (R2PD) for AB-101.
measured From ICF signature through 13 weeks after last study drug dose.
Phase 2: Determine the efficacy profile of AB-101 in combination with rituximab or in combination with bendamustine and rituximab when administered to patients with R/R NHL of B-cell origin.
measured From baseline disease assessment through end of study participation.
Permalink · ARTV's whole pipeline · Catalyst calendar · Every registered study · What changed